# NIH Fails to Institute Health ## A Tale of Two Trials The difference between efficient and inefficient trial design isn’t theoretical. Your species accidentally ran a controlled experiment on itself during COVID. Two countries. Same disease. One spent like it was trying to cure death. The other actually did. ### RECOVERY Trial (UK Approach) The British spent [\$20 million (95% CI: \$15 million-\$25 million)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-recovery_trial_total_cost) over 6 months^([1](../references.llms.md#ref-landray-recovery-trial-quote)). Enrolled 48,000 patients^([2](../references.llms.md#ref-recovery-trial-82x-cost-reduction)). Found multiple effective treatments, including dexamethasone^([3](../references.llms.md#ref-recovery-trial-summary-quote)), a steroid that had been available since 1957. It reduced COVID deaths by one-third and saved over [1 million lives (95% CI: 500 thousand lives-2 million lives)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-recovery_trial_global_lives_saved). Cost per patient: [\$500 (95% CI: \$400-\$2,500)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-recovery_trial_cost_per_patient). ### RECOVER Initiative (NIH Approach) [![RECOVER spent \$1.6 billion over four years and completed zero trials. That’s \$1.6 billion in admission tickets to a hospital that hasn’t opened yet.](../../assets/images/nih-fails-2-institute-health/nih-fails-2-institute-health-section-recover-initiative-nih-approach-bw-academic.jpg)](../../assets/images/nih-fails-2-institute-health/nih-fails-2-institute-health-section-recover-initiative-nih-approach-bw-academic.jpg) RECOVER spent \$1.6 billion over four years and completed zero trials. That’s \$1.6 billion in admission tickets to a hospital that hasn’t opened yet. Nearly 600 potential treatments for Long COVID have been identified. At RECOVERY trial efficiency ([\$500 (95% CI: \$400-\$2,500)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-recovery_trial_cost_per_patient)/patient, 5,500 patients per treatment), \$1.665 billion buys **600 completed trials**. The NIH received \$1.665 billion^([4](../references.llms.md#ref-recover-budget-update-2-3b)). Over 4 years^([5](../references.llms.md#ref-nih-recover-inefficiency)), they completed **zero**^([5](../references.llms.md#ref-nih-recover-inefficiency)). Only 15% of the budget went to clinical trials; the rest funded observational studies, data management, and administration^([6](../references.llms.md#ref-recover-funding-breakdown)). Of those enrolled, roughly 11% were in interventional trials that actually tested treatments^([7](../references.llms.md#ref-recover-initiative-patient-enrollment)). The other 89% were in observational studies, which is the medical equivalent of taking attendance at a funeral. Cost per interventional patient: \$504,500, the price of a house. Nobody got a house and nobody got cured. They got observed. Expensively. The observation was very thorough. It has been peer-reviewed. The peers also observed the patients. The patients are still sick, but they are the most well-documented sick people in the history of sickness. It gets worse. The treatments RECOVER eventually selected were called “truly absurd” by patient advocates^([8](../references.llms.md#ref-recover-treatments-underwhelming)). Low-dose naltrexone, the number one patient-requested treatment (generic, cheap, already showing results in independent studies), was excluded for over two years before finally being added in round two. David Putrino, director of rehabilitation innovation at Mount Sinai, called the spending “largely wasted”^([8](../references.llms.md#ref-recover-treatments-underwhelming)). Researchers outside RECOVER had lists of drugs to test. The system ignored them. Six hundred trials were possible with that money. Zero were completed. That is the difference between a system that tests treatments and a system that tests patience. ## The Translation Crisis: All Theory, No Medicine Basic research is not the problem. Five decades of NIH-funded science built one of the largest drug candidate pipelines in history. Researchers identified targets, characterized molecules, established safety profiles. That work was essential, and it succeeded. The problem is what happens after the discoveries are made: almost nothing. The pipeline is full. The exit is closed. COVID made this visible for the first time, but it is the institution’s default setting; the way you don’t notice a leaking roof until it rains inside. It has been raining inside for 50 years. The NIH has published several papers on indoor rain. There are over [20,000](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-fda_approved_products_count) FDA-approved drugs that are known to be safe in humans. Thousands more clinically-tested candidates are gathering dust^([9](../references.llms.md#ref-drug-repurposing-hub-collection)), including over 3,000 marketed drugs that could be repurposed for diseases nobody’s tried them on. In Alzheimer’s alone, researchers have identified hundreds of safe drugs worth testing, yet less than 10% are in active trials^([10](../references.llms.md#ref-ad-drug-repurposing-573-candidates)). And the number of clinical trials available for your grandma in St. Louis? Zero. There’s a warehouse of safe molecules that have never been systematically tested for new uses. The warehouse is full. The testing facility is closed for a team-building retreat. This is not hypothetical. In 2023, researchers published case reports of severe long COVID patients experiencing complete remission within days of receiving monoclonal antibody infusions^([11](../references.llms.md#ref-mca-long-covid-remission-case-reports)). Previously bedridden patients returned to normal lives, with remissions sustained over two years. The U.S. government had spent over \$5 billion purchasing millions of doses of these same antibodies for acute COVID^([12](../references.llms.md#ref-govt-monoclonal-antibody-stockpile)). When Omicron rendered them ineffective for acute treatment, millions of unused doses sat in refrigerated storage. Long COVID patients, having read the case reports, begged for access. They organized petitions. They cited the remissions. The government said no. The doses were authorized for acute COVID only, and the authorization had been revoked because they didn’t work for acute COVID, which meant they could not be given to anyone, for anything, ever. The antibodies matched the original variants; the long COVID patients had been infected by the original variants. Nobody tested this. Nobody ran trials. Nobody repurposed the stockpile. The first formal Phase 2 trial of monoclonal antibodies for long COVID is scheduled for mid-2026, four years after the doses were available and several years after they expired. Five billion dollars of medicine. Millions of doses. Patients who wanted them. Case reports showing they worked. The doses expired. The patients didn’t; they just kept being sick. Your government threw away the cure and kept the disease. There is a word for this. It is considered a slur against the competence of your entire species, so I will simply note that the word exists and move on. Then there’s metformin. A phase 3 RCT (COVID-OUT) showed it reduces long COVID incidence by 41%^([13](../references.llms.md#ref-covid-out-metformin-long-covid)). It costs \$4 a month. It has been generic for decades. It is globally available. The NIH guideline response: “insufficient evidence to recommend for or against”^([14](../references.llms.md#ref-nih-metformin-guidelines)). Long COVID costs \$170 billion a year. The \$4 pill that cuts it by 41% has no corporate sponsor, because nobody profits from a generic. This is the entire chapter in one sentence. To appreciate the scale: long COVID costs the U.S. an estimated \$170 billion annually in lost wages alone^([15](../references.llms.md#ref-long-covid-economic-cost-cutler)), with roughly 17 million Americans currently affected. A RECOVERY-style pragmatic trial would have cost approximately \$24 million and could have produced results in months. Instead, your government spent \$5 billion buying the medicine and is now paying \$170 billion a year in economic damage from the disease it didn’t bother to treat. The ratio of what you’re losing to what the trial would have cost is 7,083 to 1. [![Imagine a massive lake of possible treatments connected to the ocean by a drinking straw. Someone built the straw that way on purpose.](../../assets/images/nih-fails-2-institute-health/nih-fails-2-institute-health-section-the-translation-crisis-concept-rich-trial-poor-bw-academic.jpg)](../../assets/images/nih-fails-2-institute-health/nih-fails-2-institute-health-section-the-translation-crisis-concept-rich-trial-poor-bw-academic.jpg) Imagine a massive lake of possible treatments connected to the ocean by a drinking straw. Someone built the straw that way on purpose. The NIH is, by its own metrics, a publishing house that occasionally dabbles in medicine. It publishes 2.5 million funded papers annually^([16](../references.llms.md#ref-nih-annual-papers-published)). It produces approximately [50](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-current_drug_approvals_per_year) new drug approvals annually^([17](../references.llms.md#ref-global-new-drug-approvals-50-annually)). That’s a conversion rate from paper to patient of 0.002%. For every 50,000 papers, one drug reaches a human. The rest become citations in other papers, which become citations in other papers, in an infinite loop of academics reading each other’s homework. Your species calls this “research.” A more accurate term is “knowledge ouroboros.” It looks productive from the inside. From the outside, it’s a snake eating its own tail and writing a paper about the nutritional content. ### Plenty of Knowledge. No Translation. About 5% of patients have participated in clinical trials^([18](../references.llms.md#ref-clinical-trial-patient-participation-rate)). About [44.8% (95% CI: 40%-50%)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-patient_willingness_trial_participation_pct) would participate if invited^([19](../references.llms.md#ref-patient-willingness-clinical-trials)). About 9-11% have ever been invited^([19](../references.llms.md#ref-patient-willingness-clinical-trials)). Nearly half of all patients would join a trial if asked. Almost nobody asks. Your species has a room full of volunteers holding their hands up, and a system that looked at the room and decided to study the clipboard instead. The clipboard is very well-studied. It has been studied for decades. Multiple papers have been written about the clipboard. One of them won an award. The volunteers are still holding their hands up. Some of them have died. This has been noted on the clipboard. Understanding disease and testing treatments in humans are completely different activities. One requires microscopes. The other requires giving people medicine and seeing if they stop dying. In 1970, spending heavily on microscopes made sense; you didn’t know enough to test intelligently. In 2025, after 2.5 million papers a year for five decades, the ratio should have shifted. It didn’t. The NIH chose microscopes in 1970 and has not reconsidered since, which is the institutional equivalent of still crawling because you learned to crawl before you learned to walk. ## The Allocation Problem Your National Institutes of Health has the word “Health” in its name and an annual budget of **[\$47 billion (95% CI: \$45 billion-\$50 billion)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-nih_annual_budget)**. [55 million](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-global_annual_deaths_curable_diseases) of you die annually from disease^([20](../references.llms.md#ref-who-daily-deaths)). You would think those two facts would be related. They are not. Of \$247 billion the NIH spent over a decade, exactly [3.3% (95% CI: 2%-5%)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-nih_clinical_trials_spending_pct) went to testing which of the thousands of known-safe treatments actually work in humans^([21](../references.llms.md#ref-nih-phased-trial-spending-2010-2019)). The other 96.7% funded understanding disease mechanisms, translating discoveries toward (but never into) clinical use, training scientists, observational programs that spend billions watching disease without treating it, and a side quest engineering bat viruses, which is called “research” the way watching someone drown from a boat is called “lifeguarding.” Basic research is not the problem. Understanding disease is how you find candidates to test. The problem is that after 50 years and a trillion dollars, the ratio hasn’t moved. The marginal value of the 85th cent on basic research is near zero when you’re spending 3 cents on the only activity that turns research into medicine. You don’t have a knowledge deficit. You have an allocation deficit. [3.3% (95% CI: 2%-5%)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-nih_clinical_trials_spending_pct) on trials might be defensible if the testing queue were empty. It isn’t. There are roughly 9,500 compounds (95% CI: 7,000 compounds-12,000 compounds) with established safety profiles, and [99.7% (90% CI: 99%-100%)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-unexplored_ratio) of their possible disease applications have never been tested. Most are off-patent, which means no pharmaceutical company will fund trials for them, which means the NIH is the only entity that could, which means it is specifically choosing not to do the one thing only it can do. The pipeline is overflowing with candidates. The bottleneck is trials. The drugs are sitting there. Safe. Ready. Unpatentable. They’ve been waiting for decades. Some of them have been waiting longer than most of your scientists have been alive. It’s like spending 96.7% of your grocery budget on cookbooks and [3.3% (95% CI: 2%-5%)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-nih_clinical_trials_spending_pct) on food, then wondering why you’re starving. Except the cookbooks are very prestigious and the starving people aren’t on the committee that decides whether to buy more cookbooks. [![The NIH spends 96.7 percent on understanding disease and 3.3 percent on testing cures. They understand a lot.](../../assets/images/nih-fails-2-institute-health/nih-fails-2-institute-health-section-allocation-scandal-bw-academic.jpg)](../../assets/images/nih-fails-2-institute-health/nih-fails-2-institute-health-section-allocation-scandal-bw-academic.jpg) The NIH spends 96.7 percent on understanding disease and 3.3 percent on testing cures. They understand a lot. > **NOTE:** > > A JAMA study^([21](../references.llms.md#ref-nih-phased-trial-spending-2010-2019)) broke down \$247.3 billion in NIH spending (2010-2019). I have organized it from “largest amount spent not on clinical trials” to “smallest amount spent not clinical trials,” though I should note that none of it is labeled “not clinical trials.” It is labeled “investment in the future.” The future has been invested in for 50 years. It has not yet arrived. > > - **84.9% - Basic research** (\$209.9B): Understanding disease mechanisms, molecular biology, genomics. Essential for identifying new targets, but 85 cents of every dollar is a lot of understanding and not much testing. > - **11.8% - Applied research (non-trial)** (\$29.3B): Translating discoveries toward practical use, but without the final step of testing them in patients. > - **CTSA infrastructure program:** ~\$1B/year in trial infrastructure, coordination, and training^([22](../references.llms.md#ref-nih-ctsa)) > - **Observational studies:** Population health data collection (e.g., large-scale observational cohorts^([23](../references.llms.md#ref-nih-all-of-us-inefficiency)): \$2.16B). Valuable for identifying patterns, but observation without intervention doesn’t cure anyone. > - **Other applied research:** Drug characterization, health services research, epidemiology > - **3.3% - Phased clinical trials** (\$8.1B): The only category that directly tests whether treatments work in humans (Phases 1-3) > - Phase 1: \$1.5B (18.5% of clinical trial budget) > - Phase 2: \$3.5B (43.2%) > - Phase 3: \$2.6B (32.1%). **NIH covers only 3.7-4.3% of Phase 3 costs**, leaving completion to industry, which only funds trials with patent-protected profit potential. > - Other/unclassified: \$0.5B (6.2%) for cross-phase overhead, pilot studies, and trials not classified to a single phase > - Pragmatic trials^([24](../references.llms.md#ref-pragmatic-trials-cost-advantage)) ([82x (90% CI: 21.4x-195x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-recovery_trial_cost_reduction_factor) cheaper per patient): Severely underfunded despite proven efficiency ## Why This Allocation Exists This is not the fault of individual researchers. Most became scientists because they wanted to cure diseases. The system they work in rewards everything except curing diseases, and those rewards were designed by someone else entirely. [![The revolving door between pharma, government, and academia. People enter from one side and exit from the other side, richer.](../../assets/images/nih-fails-2-institute-health/nih-fails-2-institute-health-section-why-this-allocation-exists-bw-academic.jpg)](../../assets/images/nih-fails-2-institute-health/nih-fails-2-institute-health-section-why-this-allocation-exists-bw-academic.jpg) The revolving door between pharma, government, and academia. People enter from one side and exit from the other side, richer. Huge drug companies with political influence love the NIH. Taxpayers absorb the risk of basic research; industry patents whatever works. It’s like if your neighbor paid for your kitchen renovation, and then you charged them rent to eat there. But independent trials comparing drugs head-to-head? Those are terrifying. They might reveal that the \$80,000 drug works about as well as the \$4 generic. PhRMA, the pharmaceutical lobby, has consistently opposed comparative effectiveness research. When Congress created PCORI (the Patient-Centered Outcomes Research Institute) in 2010, industry successfully lobbied to prohibit it from making coverage recommendations based on cost-effectiveness^([25](../references.llms.md#ref-pcori-cost-effectiveness-prohibition)). Congress literally passed a law saying “don’t fund research that might lower drug prices.” They wrote it down. In legislation. On purpose. With their names on it. And then they went home and told their constituents they were fighting for affordable healthcare, because your species’ capacity for doublethink is genuinely Olympian. This pattern held during the deadliest pandemic in a century. Operation Warp Speed initially selected 14 vaccine candidates and planned head-to-head comparative studies in primates^([26](../references.llms.md#ref-ows-monkey-comparison-dropped)). Then dropped the comparative studies without explanation. Backed five companies with billions, gave others nothing. The selection process was opaque enough to draw Senate scrutiny; when Senator Tammy Baldwin asked BARDA’s acting director to name the companies receiving public funds, he refused, citing “procurement sensitivity”^([27](../references.llms.md#ref-ows-opaque-selection)). No published cost-benefit analysis for excluding any candidate^([28](../references.llms.md#ref-gao-21-319-ows)). The WHO ran a Solidarity Trial for Vaccines doing exactly this kind of head-to-head comparison^([29](../references.llms.md#ref-who-solidarity-trial-vaccines)). The U.S. didn’t join. Notice the pattern: PCORI is banned from comparing drug cost-effectiveness. RECOVER ignores the treatments patients actually want. OWS drops the comparative monkey studies. Every manufacturer has financial interests; Pfizer had them, Moderna had them, and that wasn’t disqualifying. “Financial interest” only becomes a reason not to test when the treatment is cheap, generic, or threatens incumbent revenue. The system tests what’s profitable and ignores what isn’t. The revolving door helps. NIH advisory committees include industry representatives. Former NIH officials join pharmaceutical boards. Academic researchers depend on industry grants. Everyone’s incentives align against cheap, fast trials testing whether expensive drugs outperform generics. It’s not a conspiracy. Conspiracies require secrecy. This is all public. It’s just that everyone involved happens to benefit from the same terrible outcome, purely by coincidence, repeatedly, for decades. There is a word for this. The word is “conspiracy.” The difference between a conspiracy and a system is whether the participants need to meet in a dark room. These people meet in conference rooms with catering. The outcome is identical. The [3.3% (95% CI: 2%-5%)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-nih_clinical_trials_spending_pct) allocation isn’t a mystery. It’s a business model. Basic research produces publications. Publications produce tenure. Tenure produces more grants. Individual researchers want cures. The system rewards them for everything except producing one. Actual treatments are a byproduct that occasionally happens when someone forgets to optimize for papers and accidentally optimizes for results instead. It’s like a restaurant where the chefs are passionate about food but get promoted based on how many menus they print. The menus are exquisite. They have won awards. The diners are eating the menus. Nobody has mentioned this. ## You Pay Twice The NIH claims to produce “public goods” like open science and training. What it actually produces is a free R&D department for pharmaceutical companies, funded by the same people who then pay full price for the drugs. [![You pay for the research. They patent the results. You pay again for the results you paid for. Humans invented this.](../../assets/images/nih-fails-2-institute-health/nih-fails-2-institute-health-section-the-public-goods-vs-club-goods-scam-bw-academic.jpg)](../../assets/images/nih-fails-2-institute-health/nih-fails-2-institute-health-section-the-public-goods-vs-club-goods-scam-bw-academic.jpg) You pay for the research. They patent the results. You pay again for the results you paid for. Humans invented this. Taxpayers funded research behind 99% of new drugs^([30](../references.llms.md#ref-nih-funded-approved-drugs)) (356 drugs, 2010-2019). Industry patents the winners. The public pays again through high drug prices. When research leads to a dead end, the public eats the loss. You pay for the lottery ticket. They cash the winnings. You’d think someone would have mentioned this arrangement before now, and someone has, many times, but the people who cash the winnings also fund the campaigns of the people who could change the arrangement, so the arrangement continues. The only things the NIH *should* fund are things private companies *cannot* profitably fund: open pragmatic trial platforms, repurposing of generic drugs where no patent means no profit means no interest, and comparative effectiveness data from head-to-head trials revealing which drugs actually work best (pharma’s nightmare, your potential salvation). Instead, the NIH explicitly avoids them to “not crowd out industry.” Translation: “We won’t run the trials that would lower drug prices, because the people who set drug prices asked us nicely.” They asked nicely and also spent [\$198 million (95% CI: \$190 million-\$210 million)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-defense_lobbying_annual) on lobbying, but the niceness was noted. ## The Patient Disconnect: Zero Correlation with Health Outcomes Correlation between NIH funding priorities and actual disease burden: **0.07**^([31](../references.llms.md#ref-nih-funding-vs-disease-burden-correlation)). That is not a typo. On a scale of 0 (random) to 1 (perfect), the NIH scores “basically a coin flip.” A dartboard would allocate research funding more rationally. A drunk person throwing darts at a list of diseases would produce a funding allocation that correlates more closely with actual disease burden than the National Institutes of Health, which employs 20,000 people and has been doing this for 50 years. The dartboard doesn’t even need to be in the building. [![NIH funding has a 0.07 correlation with disease burden. That’s worse than random. A dart-throwing monkey would do better.](../../assets/images/nih-fails-2-institute-health/nih-fails-2-institute-health-section-the-patient-disconnect-zero-bw-academic.jpg)](../../assets/images/nih-fails-2-institute-health/nih-fails-2-institute-health-section-the-patient-disconnect-zero-bw-academic.jpg) NIH funding has a 0.07 correlation with disease burden. That’s worse than random. A dart-throwing monkey would do better. Patients want medicine that works, access to experimental therapies, trials they can join, and a cure before they die. The NIH funds molecular mechanisms, research empires, and institutional overhead. These two lists do not overlap. They don’t even live in the same neighborhood. Patients don’t control the money. Committees do. And committees optimize for the continued existence of committees. This is true of all committees, everywhere, since the invention of committees. Nobody has ever convened a committee that recommended fewer committees. No sane biologist would struggle to classify an organism that exists solely to produce copies of itself. The word is “virus.” You call them “advisory panels.” [![Money goes in. Papers come out. Patients wait in the middle. The loop is working perfectly at producing papers.](../../assets/images/nih-fails-2-institute-health/nih-fails-2-institute-health-section-what-nih-funds-bw-academic.jpg)](../../assets/images/nih-fails-2-institute-health/nih-fails-2-institute-health-section-what-nih-funds-bw-academic.jpg) Money goes in. Papers come out. Patients wait in the middle. The loop is working perfectly at producing papers. ## The Human Cost of Misallocation When you allocate the vast majority of a [\$47 billion (95% CI: \$45 billion-\$50 billion)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-nih_annual_budget) annual budget into understanding disease instead of testing the safe, unpatentable treatments already gathering dust on the shelf, you get a very well-understood population of dead people. ### Cost Per Quality-Adjusted Life Year A Quality-Adjusted Life Year is one year of healthy life. Lose a leg and live ten years, that’s fewer than ten QALYs. Die at forty instead of eighty, that’s forty QALYs lost. It’s how you measure whether a medical system is keeping people alive and functional, or just keeping itself funded. The ADAPTABLE trial proved pragmatic trials cost [44.1x (90% CI: 12.8x-210x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-dfda_trial_cost_reduction_factor) less per patient than traditional RCTs^([24](../references.llms.md#ref-pragmatic-trials-cost-advantage)) ([\$929 (95% CI: \$929-\$1,400)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-adaptable_trial_cost_per_patient) vs [\$41,000 (95% CI: \$20,000-\$120,000)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-traditional_phase3_cost_per_patient)). Same science. Fewer catered meetings. [44.1x (90% CI: 12.8x-210x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-dfda_trial_cost_reduction_factor) more patients enrolled. Fewer conference rooms rented. [![One method saves lives efficiently. The other publishes papers expensively. You’re currently funding the papers.](../../assets/images/nih-fails-2-institute-health/nih-fails-2-institute-health-section-cost-per-qaly-bw-academic.jpg)](../../assets/images/nih-fails-2-institute-health/nih-fails-2-institute-health-section-cost-per-qaly-bw-academic.jpg) One method saves lives efficiently. The other publishes papers expensively. You’re currently funding the papers. ### The Preventable Deaths Conservative estimate: the NIH’s misallocation costs approximately 10 million QALYs and 700,000 preventable deaths every year. The upper bound is far worse (100 million QALYs, 7 million deaths), but even the floor is staggering. A rational civilization, upon discovering its budget allocation was killing 700,000 people a year, would adjust the budget allocation. Your species adjusted the font on the annual report. Traditional clinical trials run at [2.27% (90% CI: 0.476%-7.84%)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-nih_traditional_trial_max_efficiency_pct) the efficiency of pragmatic trials. And that’s the ceiling, because it only accounts for the sliver of the NIH budget that goes to trials at all. If your car ran at [2.27% (90% CI: 0.476%-7.84%)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-nih_traditional_trial_max_efficiency_pct) efficiency, you would push it faster than it drives. If your heart pumped at [2.27% (90% CI: 0.476%-7.84%)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-nih_traditional_trial_max_efficiency_pct) efficiency, you’d be dead before finishing this sentence. Your clinical trial system runs at [2.27% (90% CI: 0.476%-7.84%)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-nih_traditional_trial_max_efficiency_pct) efficiency, and you gave it a raise. You gave it a raise and a new building. The building has a cafeteria. > **NOTE:** > > COVID is the most vivid example of what misallocation costs. So let me tell you what happened, and I will try to keep my composure, though I should warn you that I have been told I do not have composure. > > Your government knew this research was dangerous. In 2014, the Obama administration imposed a moratorium on gain-of-function research, specifically because engineering novel viruses posed pandemic risk^([32](../references.llms.md#ref-obama-gof-moratorium-2014)). The government’s own assessment: too dangerous to continue. In December 2017, the moratorium was lifted^([33](../references.llms.md#ref-nih-gof-moratorium-lifted-2017)). There is evidence that NIH officials may have effectively circumvented the pause the entire time regardless^([34](../references.llms.md#ref-reason-trump-lab-leak-blame)). At no point, before the moratorium, during it, or after lifting it, did anyone publish a cost-benefit analysis showing the expected benefits of engineering novel coronaviruses exceeded the risk of starting a pandemic. The question was never formally asked. It was not even formally avoided. It simply did not occur to anyone that the question should exist, which is the kind of oversight that is forgivable when you’re deciding where to put a mailbox and less forgivable when you’re deciding whether to make new viruses. > > Through a grant to EcoHealth Alliance, the NIH sent \$600,000 to the Wuhan Institute of Virology for research engineering novel bat coronaviruses^([35](../references.llms.md#ref-nih-ecohealth-wiv-grant)). In 2018 and 2019, one of those engineered viruses turned out to be unexpectedly more infectious in mice^([36](../references.llms.md#ref-nih-ecohealth-gof-admission)). EcoHealth was required to report this immediately; they did not report it for nearly two years^([37](../references.llms.md#ref-gao-nih-oversight-ecohealth)). The NIH was required to oversee the grant; a federal watchdog found they did not^([37](../references.llms.md#ref-gao-nih-oversight-ecohealth)). The NIH’s own deputy director later admitted in congressional testimony that this was gain-of-function research^([38](../references.llms.md#ref-tabak-gof-testimony-2024)). I am losing my composure. > > The FBI, the Department of Energy, and the CIA (as of January 2025) have all assessed that a lab leak is the most likely origin of COVID-19^([39](../references.llms.md#ref-cia-lab-leak-assessment-2025)). A two-year congressional investigation concluded the same^([40](../references.llms.md#ref-covid-select-final-report-2024)). This is not proven beyond doubt; four intelligence agencies still lean toward natural origin. But the question is not “who is to blame?” It is: what does it cost when an institution allocates \$600,000 to a side quest creating bat viruses instead of testing treatments? > > If these assessments are correct: \$14 to \$16 trillion in economic damage to the United States alone^([41](../references.llms.md#ref-covid-16-trillion-virus),[42](../references.llms.md#ref-covid-14-trillion-usc)). Seven million confirmed deaths, 19 to 36 million by excess mortality estimates^([43](../references.llms.md#ref-who-covid-deaths)). An ongoing \$1 trillion per year in global long COVID costs^([44](../references.llms.md#ref-long-covid-global-trillion)). The NIH’s entire budget over its 50-year history, inflation-adjusted, is approximately \$1.1 trillion. A single unsupervised grant may have cost humanity roughly 13 times more than everything the NIH has ever spent, on everything, combined, since 1970. Your species does not have a unit of measurement for this level of institutional failure. This is, itself, a failure of measurement. > > Nobody intended this outcome. The researchers were studying bat coronaviruses to prevent pandemics, which is a goal I would applaud if it had not produced the opposite result. The grant administrators were following procedures. The system did not fail because of villains. It failed because nobody’s job was to ask: “Is engineering novel coronaviruses in a city with inadequate biosafety protocols a better use of \$600,000 than testing whether any of the thousands of safe, untested compounds on the shelf might cure a disease that is killing people right now?” > > That question was never asked because the system is not designed to ask it. The system is designed to fund research. Whether that research helps anyone is a separate question, handled by a separate department, which does not exist. Most buildings have a department called “the point.” Every other department reports to it. Your species organized the entire building and forgot to include the point. The building is very well organized. > > Then the pandemic happened. Then 7 million people died. Then the NIH received \$1.7 billion to address the long-term damage. Then it spent 85% of that money watching people be sick instead of testing treatments. I have now fully lost my composure. > > In that timeline, the NIH is too busy testing cures to fund gain-of-function research in Wuhan. There is no COVID-19 pandemic. There is no \$16 trillion in economic damage. There are no 7 million dead. There is no long COVID costing \$1 trillion a year. ## The Track Record You have already seen the numbers: \$1.1 trillion over 50 years, zero diseases eradicated (one possibly created)^([45](../references.llms.md#ref-nih-eradicated-zero-diseases)). I asked the NIH how many diseases they’ve eradicated. They sent me a 40-page document about their strategic vision. I read all 40 pages. The number wasn’t in it. The word “eradicate” wasn’t in it either. The word “strategic” was in it 31 times. The WHO eradicated smallpox for \$300 million^([46](../references.llms.md#ref-smallpox-eradication-roi)). Jonas Salk developed the polio vaccine in a university lab and gave it away for free, which is why nobody at the NIH talks about him at parties because he makes everyone look bad by comparison and also he’s dead, which is the thing they were supposed to be fixing. He gave away the patent. I asked an NIH official what would happen if they gave away patents today and they made a sound I can only describe as a laugh, but sadder. Veterinarians have eradicated multiple animal diseases^([47](../references.llms.md#ref-animal-diseases-eradicated-by-vets)) on budgets the NIH would consider a rounding error. Your veterinarians eradicated hog cholera. Pigs. I should note the irony of humanity’s failure to eradicate human diseases while more aggressively finding cures for animals you lock in metal crates too small to turn around in, standing in their own waste, whose tails you amputate without anesthesia because the confinement drives them insane enough to eat each other. But fixed that cholera for ya! ## What Would Actually Work The RECOVERY trial already proved it. [\$500 (95% CI: \$400-\$2,500)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-recovery_trial_cost_per_patient) per patient instead of [\$41,000 (95% CI: \$20,000-\$120,000)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-traditional_phase3_cost_per_patient). First life-saving result in under 100 days^([48](../references.llms.md#ref-recovery-trial-100-days-to-cure)). Over [1 million lives (95% CI: 500 thousand lives-2 million lives)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-recovery_trial_global_lives_saved) saved. The blueprint exists. It is not theoretical. It happened. In England. During a pandemic. While Americans were arguing about horse dewormer. The British did not use a special technique. They did not have access to secret technology. They used the same drugs, the same disease, the same species of patient. They just tested the drugs on the patients instead of writing about the drugs near the patients. This is the breakthrough. It took zero breakthroughs. The evidence is right there. It’s not hiding. It’s waving at you. It has been waving at you for years. Now imagine the other timeline. Not as an indictment, but as a measure of what was lost. If the NIH had allocated even 20% of its \$1.1 trillion to pragmatic trials over 50 years (the remaining 80% still on basic research), that produces 440 million patient-trials at RECOVERY efficiency ([\$500 (95% CI: \$400-\$2,500)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-recovery_trial_cost_per_patient) per patient). That is enough to test every safe compound against every major disease, multiple times, with replication. The Oxford RECOVERY trial tested 48,000 patients and found a treatment that saved over a million lives, in 100 days, for \$24 million. Multiply that across 440 million patients and 50 years and the number of lives saved becomes difficult to calculate because the diseases start disappearing and the math changes. In that timeline, the NIH’s \$1.1 trillion produces what a trillion dollars should produce: the systematic eradication of disease after disease after disease, because you finally pointed the money at the thing that actually works. The difference between that timeline and this one is not a matter of hindsight. The Oxford RECOVERY trial happened. Pragmatic trials existed the entire time. The efficiency data was available for decades. The counterfactual is not imaginary. It is the road you could see, that was paved, that had signs on it, that other countries were already driving on. You chose the other road. It led here. I am told that on your planet, describing this situation accurately is considered “rude.” Not describing it is called “complicity.” I will risk the rudeness. The recipe is simple enough that I can state it in four sentences: 1. **Pay for results.** Treatment equals payment, no treatment equals no payment. 2. **Publish everything, including failures.** Especially failures, because the people who will die if the system fails are more motivated than the people who get tenure if the system continues. 3. **Eliminate gatekeepers and let patients vote with participation.** The volunteers are still holding their hands up. 4. **Automate administration with transparent systems instead of committees.** Committees cannot be trusted (see above, and also see the entire history of committees, and also see the committee that was formed to investigate whether committees can be trusted, which concluded that committees are essential). The cost of not doing this is measurable. Over 50% of trial results are never published^([49](../references.llms.md#ref-publication-bias-clinical-trials)), which means researchers unknowingly repeat experiments that already failed. This is how your species wastes an estimated 85% of its \$200 billion annual research investment^([50](../references.llms.md#ref-glasziou-chalmers-research-waste)), and then passes the cost to patients as higher drug prices. The blueprint for this system is [your decentralized FDA](../../knowledge/solution/dfda.llms.md)^([51](../references.llms.md#ref-dfda-spec-paper-2025),[52](../references.llms.md#ref-dfda-impact-paper-2025)). The funding mechanism is [the 1% treaty](https://manual.warondisease.org/knowledge/solution/1-percent-treaty.html)^([53](../references.llms.md#ref-1-percent-treaty-paper-2025)) ^([54](../references.llms.md#ref-1-pct-treaty-impact-paper-2025)). The next chapters explain both. 1\. Sir Martin Landray. Landray, sir martin, on the RECOVERY trial. *Sir Martin Landray* *In 2019, I had no idea that I would be setting up a trial of treatments for an infectious disease, let alone a pandemic virus. I certainly would not have thought it possible to go from a blank piece of paper to enrolling the first patient in nine days, to finding the first life-saving treatment within ten weeks, and for it to be made standard NHS policy within three hours. Additional sources: https://www.ox.ac.uk/news/features/recovery-trial-two-years* . 2\. Manhattan Institute. RECOVERY trial 82× cost reduction. *Manhattan Institute: Slow Costly Trials* *RECOVERY trial:  \$500 per patient (\$20M for 48,000 patients = \$417/patient) Typical clinical trial:  \$41,000 median per-patient cost Cost reduction:  80-82× cheaper (\$41,000 ÷ \$500 ≈ 82×) Efficiency: \$50 per patient per answer (10 therapeutics tested, 4 effective) Dexamethasone estimated to save \>630,000 lives Additional sources: https://manhattan.institute/article/slow-costly-clinical-trials-drag-down-biomedical-breakthroughs \| https://pmc.ncbi.nlm.nih.gov/articles/PMC9293394/* . 3\. Oxford University News. RECOVERY trial summary quote. *Oxford University News* *One trial. Over 47,000 participants. Nearly 200 hospital sites, across six countries. Ten results. Four effective COVID-19 treatments... Through discovering four treatments that effectively reduce deaths from COVID-19, it is certain that the study has saved thousands – if not millions – of lives worldwide. Additional sources: https://www.ox.ac.uk/news/features/recovery-trial-two-years* . 4\. RECOVER Initiative. RECOVER initiative budget update (\>\$2.3B). *RECOVER Initiative* (2024). 5\. RECOVER Initiative & News Reports. NIH RECOVER initiative inefficiency. *RECOVER Initiative & News Reports* (2025). 6\. RECOVER Initiative. [Funding \| RECOVER COVID initiative](https://recovercovid.org/funding). (2024). 7\. NIH. NIH RECOVER initiative patient enrollment numbers. *NIH: RECOVER Initiative Enrollment* *Enrolled:  30,000 people in ongoing studies and clinical trials Goal: 40,000 adults and children \$1.15B effort (including American Rescue Plan Act 2021 support) One of largest, most diverse Long COVID cohorts in world Additional sources: https://www.nih.gov/news-events/news-releases/nih-builds-large-nationwide-study-population-tens-thousands-support-research-long-term-effects-covid-19 \| https://recovercovid.org/news/nih-launches-long-covid-clinical-trials-through-recover-initiative-opening-enrollment* . 8\. Ladyzhets, B. ’Underwhelming’: NIH trials fail to test meaningful long Covid treatments – after 2.5 years and \$1 billion. *STAT News* (2023) *Patient advocates called RECOVER’s treatment selections “truly absurd” (Jaime Seltzer, \#MEAction). David Putrino (Mount Sinai) said funding “has been largely wasted.” Low-dose naltrexone, the top patient-requested treatment, was excluded for over 2 years before being added in round 2.* 9\. Broad Institute. Drug repurposing hub (broad institute). *Broad Institute* (2017) *The Drug Repurposing Hub contains 4,707 hand-curated compounds (later expanded to 6,801), including 3,422 drugs that are marketed or have been in clinical trials. The collection includes 1,988 approved/marketed drugs and 1,348 compounds that cleared at least phase 1 clinical testing. Additional sources: https://www.broadinstitute.org/drug-repurposing-hub \| https://pmc.ncbi.nlm.nih.gov/articles/PMC5568558/* . 10\. Grabowska, M. E., Huang, A., Wen, Z., Li, B. & Wei, W.-Q. [Drug repurposing for alzheimer’s disease from 2012-2022: A 10-year literature review](https://doi.org/10.3389/fphar.2023.1257700). *Frontiers in Pharmacology* **14**, 1257700 (2023) *573 unique drugs were proposed for repurposing in Alzheimer’s disease over the last 10 years, including drugs acting on the nervous system (17%), antineoplastic and immunomodulating agents (16%), and drugs acting on the cardiovascular system (12%). 61% of reviewed studies performed validation, yet only 4% used real-world data.* 11\. Swank, Z. *et al.* Remission of severe forms of long COVID following monoclonal antibody (MCA) infusions: A report of signal index cases and call for targeted research. *Journal of Infectious Diseases* (2023). 12\. Department of Health and Human Services. [U.S. Government monoclonal antibody purchases for COVID-19 treatment](https://medicalcountermeasures.gov/newsroom/2021/regeneronpurchase). (2022). 13\. Bramante, C. T. *et al.* [Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): A multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial](https://doi.org/10.1016/S1473-3099(23)00299-2). *The Lancet Infectious Diseases* **23**, 1119–1129 (2023). 14\. National Institutes of Health. [Metformin – COVID-19 treatment guidelines](https://www.covid19treatmentguidelines.nih.gov/therapies/miscellaneous-drugs/metformin/). (2024). 15\. Cutler, D. M. The economic cost of long COVID: An update. *Harvard Kennedy School, Mossavar-Rahmani Center for Business and Government* (2022). 16\. NSF. Annual number of papers published from NIH-funded research. *NSF: Publications Output* *Global scientific output: 2.5-2.6 million research papers published annually (all sources, not just NIH) Worldwide S&E publication growth: 1.8M (2008) → 2.6M articles (2018), averaging  4% annual growth NIH-specific output example (2000): 4,451 R01 grants (\$1.3B) produced 55,000 publications, 3.7M citations Total active journals: 46,736 peer-reviewed journals (2020) publishing 3M+ articles annually Additional sources: https://ncses.nsf.gov/pubs/nsb20206 \| https://ourworldindata.org/grapher/scientific-publications-per-million \| https://pmc.ncbi.nlm.nih.gov/articles/PMC8738817/* . 17\. C&EN. Annual number of new drugs approved globally:  50. *C&EN* (2025) *50 new drugs approved annually Additional sources: https://cen.acs.org/pharmaceuticals/50-new-drugs-received-FDA/103/i2 \| https://www.fda.gov/drugs/development-approval-process-drugs/novel-drug-approvals-fda* . 18\. ACS CAN. Clinical trial patient participation rate. *ACS CAN: Barriers to Clinical Trial Enrollment* *Only 3-5% of adult cancer patients in US receive treatment within clinical trials About 5% of American adults have ever participated in any clinical trial Oncology: 2-3% of all oncology patients participate Contrast: 50-60% enrollment for pediatric cancer trials (\<15 years old) Note:  20% of cancer trials fail due to insufficient enrollment; 11% of research sites enroll zero patients Additional sources: https://www.fightcancer.org/policy-resources/barriers-patient-enrollment-therapeutic-clinical-trials-cancer \| https://hints.cancer.gov/docs/Briefs/HINTS_Brief_48.pdf* . 19\. Trials. Patient willingness to participate in clinical trials. *Trials: Patients’ Willingness Survey* *Recent surveys: 49-51% willingness (2020-2022) - dramatic drop from 85% (2019) during COVID-19 pandemic Cancer patients when approached: 88% consented to trials (Royal Marsden Hospital) Study type variation: 44.8% willing for drug trial, 76.2% for diagnostic study Top motivation: "Learning more about my health/medical condition" (67.4%) Top barrier: "Worry about experiencing side effects" (52.6%) Additional sources: https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-015-1105-3 \| https://www.appliedclinicaltrialsonline.com/view/industry-forced-to-rethink-patient-participation-in-trials \| https://pmc.ncbi.nlm.nih.gov/articles/PMC7183682/* . 20\. World Health Organization. The top 10 causes of death. *WHO Fact Sheets* (2024) *Approximately 150,000 people die every day worldwide. The majority of these deaths (over 100,000) are from non-communicable diseases including cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes.* 21\. PMC. NIH phased trial spending for approved drugs 2010-2019. *PMC* *NIH spent \$8.1 billion on phased clinical trials of 387 drugs that were approved between 2010 and 2019. Additional sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10349341/* . 22\. National Center for Advancing Translational Sciences. [Clinical and translational science awards (CTSA) program](https://ncats.nih.gov/research/research-activities/ctsa). (2025). 23\. All of Us. NIH all of us research program outcomes and spending. *All of Us: Program Overview* (2026) *Total authorized funding:  \$2.16B (not \$4B) - \$1.02B allocated since 2015, \$1.14B authorized through 2026 via 21st Century Cures Act Budget cut 71% over 2 years: \$500M+ (2023) → \$150M (2025) Enrolled: 860,000 participants from all 50 states; 633,000+ participants with data available for research Clinical trials completed: Zero (program is observational cohort study, not a clinical trial program) Purpose: Collect prospective data to inform future clinical trials, provide recruitment infrastructure Additional sources: https://allofus.nih.gov/article/program-overview \| https://www.nejm.org/doi/full/10.1056/NEJMsr1809937 \| https://www.genomeweb.com/sequencing/all-us-research-program-unfazed-funding-cuts-lays-out-plans-through-2026* . 24\. NIH Common Fund. NIH pragmatic trials: Minimal funding despite 30x cost advantage. *NIH Common Fund: HCS Research Collaboratory* (2025) *The NIH Pragmatic Trials Collaboratory funds trials at \$500K for planning phase, \$1M/year for implementation-a tiny fraction of NIH’s budget. The ADAPTABLE trial cost \$14 million for 15,076 patients (= \$929/patient) versus \$420 million for a similar traditional RCT (30x cheaper), yet pragmatic trials remain severely underfunded. PCORnet infrastructure enables real-world trials embedded in healthcare systems, but receives minimal support compared to basic research funding. Additional sources: https://commonfund.nih.gov/hcscollaboratory \| https://pcornet.org/wp-content/uploads/2025/08/ADAPTABLE_Lay_Summary_21JUL2025.pdf \| https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604499/* . 25\. U.S. Congress. [42 u.s. Code § 1320e-1 - limitations on certain uses of comparative clinical effectiveness research](https://www.law.cornell.edu/uscode/text/42/1320e-1). (2010) *Exact statutory text: "The Patient-Centered Outcomes Research Institute established under section 1320e(b)(1) of this title shall not develop or employ a dollars-per-quality adjusted life year (or similar measure that discounts the value of a life because of an individual’s disability) as a threshold to establish what type of health care is cost effective or recommended." The Secretary also cannot use such thresholds for Medicare coverage or reimbursement decisions.* 26\. Cohen, J. Saying human trials aren’t enough, researchers call for comparison of COVID-19 vaccines in monkeys. *Science* (2020) doi:[10.1126/science.370.6513.154](https://doi.org/10.1126/science.370.6513.154). 27\. Cohen, J. Operation Warp Speed’s opaque choices of COVID-19 vaccines draw Senate scrutiny. *Science* (2020). 28\. U.S. Government Accountability Office. *Accelerated COVID-19 Vaccine Development Status and Efforts to Address Manufacturing Challenges (Operation Warp Speed)*. (2021). 29\. World Health Organization. [WHO statement on Solidarity Trial Vaccines](https://www.who.int/news/item/26-10-2021-who-statement-on-solidarity-trial-vaccines). (2021). 30\. HHS. FY2016 budget in brief - NIH. *HHS* (2020) *NIH funding contributed to published research associated with every one of the 356 new drugs approved by the FDA from 2010–2019." Total NIH spending on this research was \$187 billion, while industry spending on clinical development for these drugs was significantly higher. Approximately 54% of the NIH research budget is devoted to basic biomedical and behavioral research, while about one-third (33%) is allocated to clinical research including patient-oriented research, clinical trials, and health services research. Categories overlap so totals exceed 100%. Additional sources: https://www.pnas.org/doi/10.1073/pnas.1920929117 \| https://marianamazzucato.com/books/the-entrepreneurial-state \| https://www.hhs.gov/about/budget/budget-in-brief/nih/index.html \| https://www.hhs.gov/about/budget/budget-in-brief/nih/index.html* . 31\. ScienceDirect. Correlation between NIH funding priorities and disease burden. *ScienceDirect: Persistence of Very Low Correlations* *Very weak correlations: R² \< 0.03 between NIH funding and 5 disease burden measures for 27 diseases Historical (1996): r=0.62 correlation with DALYs, but explained only 39% of variance Recent (2008-2019): Simple correlation 0.08 between disease burden increases and funding increases 2019 analysis: Only 29% of variance in NIH funding explained by disease burden Strongest predictor of 2019 funding: 2008 funding levels (r=0.88), revealing long-standing inefficiencies Additional sources: https://www.sciencedirect.com/science/article/pii/S2666535224001174 \| https://www.nejm.org/doi/full/10.1056/NEJM199906173402406 \| https://pmc.ncbi.nlm.nih.gov/articles/PMC3044706/* . 32\. White House Office of Science and Technology Policy. [U.s. Government gain-of-function deliberative process and research funding pause on selected gain-of-function research involving influenza, MERS, and SARS viruses](https://www.phe.gov/s3/dualuse/Documents/gain-of-function.pdf). (2014). 33\. National Institutes of Health. [Notice announcing the removal of the funding pause for gain-of-function research projects](https://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-071.html). (2017). 34\. staff, R. Is donald trump to blame for a COVID lab leak? *Reason* (2025). 35\. NIAID. [SARS-CoV-2 and NIAID-supported bat coronavirus research](https://www.niaid.nih.gov/diseases-conditions/coronavirus-bat-research). (2021). 36\. Kaiser, J. [NIH says grantee failed to report experiment in Wuhan that created a bat virus that made mice sicker](https://www.science.org/content/article/nih-says-grantee-failed-report-experiment-wuhan-created-bat-virus-made-mice-sicker). *Science* (2021). 37\. Kaiser, J. [Federal watchdog finds problems with NIH oversight of grant funding bat virus research in China](https://www.science.org/content/article/federal-watchdog-finds-problems-nih-oversight-grant-funding-bat-virus-research-china). *Science* (2023). 38\. House Committee on Oversight and Government Reform. [Hearing wrap up: NIH refutes EcoHealth’s testimony, Tabak reveals federal grant procedures in need of serious reform](https://oversight.house.gov/release/hearing-wrap-up-nih-repeatedly-refutes-ecohealth-alliance-president-dr-peter-daszaks-testimony-tabak-testimony-reveals-federal-grant-procedures-in-need-of-serious-reform/). (2024). 39\. Dilanian, K. [CIA shifts assessment on Covid origins, saying lab leak likely caused outbreak](https://www.nbcnews.com/politics/politics-news/cia-shifts-assessment-covid-origins-saying-lab-leak-likely-caused-outb-rcna189284). *NBC News* (2025). 40\. Select Subcommittee on the Coronavirus Pandemic. [Final report: COVID select concludes 2-year investigation, issues 500+ page final report](https://oversight.house.gov/release/final-report-covid-select-concludes-2-year-investigation-issues-500-page-final-report-on-lessons-learned-and-the-path-forward/). (2024). 41\. Cutler, D. M. & Summers, L. H. [The COVID-19 pandemic and the \$16 trillion virus](https://jamanetwork.com/journals/jama/fullarticle/2771764). *JAMA* **324**, 1495–1496 (2020). 42\. USC Schaeffer Center. COVID-19’s total cost to the U.S. Economy will reach \$14 trillion by end of 2023. *USC Schaeffer Center for Health Policy and Economics* (2023). 43\. World Health Organization. [WHO dashboard: COVID-19 deaths](https://data.who.int/dashboards/covid19/deaths). (2026). 44\. CIDRAP. Long COVID takes \$1 trillion global economic toll each year, analysis suggests. *CIDRAP News* (2024). 45\. PMC. Number of diseases eradicated by the NIH. *PMC: Six Challenges in Eradication* *Diseases eradicated globally: Only 2 (smallpox in 1979 via \$300M WHO effort over \<10 years; rinderpest) NIH role: Contributor to research/vaccine development but not sole eradicator Near-eradication: Polio (close to achievement); measles, rubella targeted for eradication Major achievements via vaccination: Smallpox eradicated, polio nearly eliminated, diphtheria/tetanus/measles greatly reduced Impact: Vaccination eliminated disease in populations with high implementation rates; past 2 centuries saw enormous infectious disease control via sanitation, vaccines, antibiotics, nutrition Additional sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC7612385/ \| https://pmc.ncbi.nlm.nih.gov/articles/PMC4024226/ \| https://www.ncbi.nlm.nih.gov/books/NBK98117/* . 46\. CSIS. Smallpox eradication ROI. *CSIS* . 47\. Our World in Data. Animal diseases eradicated by veterinary science. *Our World in Data: Rinderpest Eradication* *Rinderpest eradicated in 2011 - only second disease ever eradicated after smallpox Declared globally eradicated by UN FAO and World Organisation for Animal Health Greatest veterinary achievement of our time" - devastating livestock disease for centuries Note: Caused up to 90% mortality in affected herds. Eradication achieved through coordinated international vaccination campaign launched in 1994 Additional sources: https://ourworldindata.org/how-rinderpest-was-eradicated \| https://www.woah.org/en/disease/rinderpest/* . 48\. University of Oxford. RECOVERY trial time to first cure. *University of Oxford* (2020) *100 days to first cure Additional sources: https://www.ox.ac.uk/news/2020-06-16-dexamethasone-reduces-death-hospitalised-patients-severe-respiratory-complications \| https://www.recoverytrial.net/news/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19* . 49\. AllTrials. Publication rate of clinical trial results. *AllTrials: Half of Trials Unreported* (2013) * 50.0% of clinical trials never publish results (NHS-funded systematic review, 2010) Schmucker et al (2014): 53% of trials published (analyzing 39 studies, \>20,000 trials) Munch et al (2014): 46% of pain treatment trials published Chang et al (2015): 49% of high-risk cardiac device trials published Positive findings: 3X more likely to be published than negative results Antidepressant example: Published literature showed 94% positive trials; FDA analysis showed only 51% positive Additional sources: https://www.alltrials.net/news/half-of-all-trials-unreported/ \| https://www.nature.com/articles/nature.2013.14286 \| https://pmc.ncbi.nlm.nih.gov/articles/PMC8276556/* . 50\. Chalmers, I. & Glasziou, P. [Avoidable waste in the production and reporting of research evidence](https://doi.org/10.1016/S0140-6736(09)60329-9). *The Lancet* **374**, 86–89 (2009) *An estimated 85% of research investment is wasted. Over 50% of studies are never published. Of \$200 billion spent annually on biomedical research globally, approximately \$170 billion is wasted through problems in research design, conduct, and reporting.* 51\. Sinn, M. P. *The Continuous Evidence Generation Protocol: Two-Stage Validation (RWE → Pragmatic Trials)*. (2025) doi:[10.5281/zenodo.18203375](https://doi.org/10.5281/zenodo.18203375) *We present the Predictor Impact Score (PIS), a novel composite metric operationalizing Bradford Hill causality criteria for automated signal detection from aggregated N-of-1 observational studies. Combined with pragmatic trial confirmation (based on evidence from 108+ embedded trials), this two-stage framework would generate validated outcome labels at 44.1x lower cost than traditional Phase III trials. This enables continuous, population-scale pharmacovigilance and precision dosing recommendations.* 52\. Sinn, M. P. *Ubiquitous Pragmatic Trial Impact Analysis*. (2025) doi:[10.5281/zenodo.18243914](https://doi.org/10.5281/zenodo.18243914) *Only 15 diseases/year get their first treatment each year. With 6,650 diseases lacking effective treatments, the backlog would take 443 years to clear. Integrating pragmatic trials into standard healthcare increases trial capacity 12.3x, cutting that timeline from 443 years to 36 years. The average untreated disease gets a treatment 212 years earlier, saving 10.7 billion deaths at \$9.62 per year of healthy life saved.* 53\. Sinn, M. P. *The 1% Treaty*. (2025) doi:[10.5281/zenodo.20076511](https://doi.org/10.5281/zenodo.20076511) *Your governments possess nuclear weapons sufficient to end civilization 122 times but have not cured Alzheimer’s once. This treaty asks them to be 1% more rational.* 54\. Sinn, M. P. *The 1% Treaty: An Incentive-Compatible Approach to Ending War and Disease*. (2025) doi:[10.5281/zenodo.18161560](https://doi.org/10.5281/zenodo.18161560) *6,650 diseases have zero FDA-approved treatments; at current trial capacity, exploring them takes  443 years. Redirecting 1% of military spending scales capacity 12.3x, cutting the timeline to  36 years and preventing 10.7 billion deaths. At \$0.02/DALY, 9.3kx more cost-effective than the best existing interventions. The result holds across every specified adoption pathway.* 55\. FDA. FDA-approved prescription drug products (20,000+). *FDA* *There are over 20,000 prescription drug products approved for marketing. Additional sources: https://www.fda.gov/media/143704/download* . 56\. OpenSecrets. Defense sector lobbying summary. *OpenSecrets* (2025) *Military sector federal lobbying totaled \$198,009,793 in 2025, up from \$159.5 million in 2024 and \$142.9 million in 2023. Additional sources: https://www.opensecrets.org/federal-lobbying/sectors/summary?id=D* . 57\. NIH. NIH budget (FY 2025). *NIH* (2024) *The budget total of \$47.7 billion also includes \$1.412 billion derived from PHS Evaluation financing... Additional sources: https://www.nih.gov/about-nih/organization/budget \| https://officeofbudget.od.nih.gov/* . 58\. Bentley et al. NIH spending on clinical trials:  3.3%. *Bentley et al.* (2023) *NIH spent \$8.1 billion on clinical trials for approved drugs (2010-2019), representing 3.3% of relevant NIH spending. Additional sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10349341/ \| https://catalyst.harvard.edu/news/article/nih-spent-8-1b-for-phased-clinical-trials-of-drugs-approved-2010-19-10-of-reported-industry-spending/* . 59\. Oren Cass, Manhattan Institute. RECOVERY trial cost per patient. *Oren Cass* (2023) *The RECOVERY trial, for example, cost only about \$500 per patient... By contrast, the median per-patient cost of a pivotal trial for a new therapeutic is around \$41,000. Additional sources: https://manhattan.institute/article/slow-costly-clinical-trials-drag-down-biomedical-breakthroughs* . 60\. NHS England; Águas et al. RECOVERY trial global lives saved ( 1 million). *NHS England: 1 Million Lives Saved* (2021) *Dexamethasone saved  1 million lives worldwide (NHS England estimate, March 2021, 9 months after discovery). UK alone: 22,000 lives saved. Methodology: Águas et al. Nature Communications 2021 estimated 650,000 lives (range: 240,000-1,400,000) for July-December 2020 alone, based on RECOVERY trial mortality reductions (36% for ventilated, 18% for oxygen-only patients) applied to global COVID hospitalizations. June 2020 announcement: Dexamethasone reduced deaths by up to 1/3 (ventilated patients), 1/5 (oxygen patients). Impact immediate: Adopted into standard care globally within hours of announcement. Additional sources: https://www.england.nhs.uk/2021/03/covid-treatment-developed-in-the-nhs-saves-a-million-lives/ \| https://www.nature.com/articles/s41467-021-21134-2 \| https://pharmaceutical-journal.com/article/news/steroid-has-saved-the-lives-of-one-million-covid-19-patients-worldwide-figures-show \| https://www.recoverytrial.net/news/recovery-trial-celebrates-two-year-anniversary-of-life-saving-dexamethasone-result* . 61\. FDA Study via NCBI. Trial costs, FDA study. *FDA Study via NCBI* *Overall, the 138 clinical trials had an estimated median (IQR) cost of \$19.0 million (\$12.2 million-\$33.1 million)... The clinical trials cost a median (IQR) of \$41,117 (\$31,802-\$82,362) per patient. Additional sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6248200/* . 62\. World Health Organization. WHO global health estimates 2024. *World Health Organization* (2024) *Comprehensive mortality and morbidity data by cause, age, sex, country, and year Global mortality:  55-60 million deaths annually Lives saved by modern medicine (vaccines, cardiovascular drugs, oncology):  12M annually (conservative aggregate) Leading causes of death: Cardiovascular disease (17.9M), Cancer (10.3M), Respiratory disease (4.0M) Note: Baseline data for regulatory mortality analysis. Conservative estimate of pharmaceutical impact based on WHO immunization data (4.5M/year from vaccines) + cardiovascular interventions (3.3M/year) + oncology (1.5M/year) + other therapies. Additional sources: https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates* .